Kolexia
Vergnenegre Alain Pneumologie
Vergnenegre Alain
Pneumologie
Hôpital Dupuytren
Limoges, France
236 Activités
345 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Métastase tumorale Carcinome épidermoïde Récidive tumorale locale Carcinomes Adénocarcinome pulmonaire Adénocarcinome

Collaborateurs

Voir plus
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Monnet Isabelle
Monnet Isabelle
Centre Hospitalier Intercommunal Créteil, Créteil, France
Le Caer Herve
Le Caer Herve
Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France
Egenod Thomas
Egenod Thomas
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
AstraZeneca
26 collaboration(s)
Dernière en 2023
Amgen
11 collaboration(s)
Dernière en 2023
MSD
10 collaboration(s)
Dernière en 2023
Sanofi
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
BREC: Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer
Essai Clinique (Spanish Lung Cancer Group)   29 janvier 2024
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Essai Clinique (OncoC4, Inc.)   17 janvier 2024
CheckMate 227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Essai Clinique (BMS)   05 janvier 2024
Initiation de l’étude ARSENAL : cohorte en vie réelle sur l’utilisation et l’efficacité du durvalumab dans le traitement de 1L du CBPC-SE en France
28e Congrès de Pneumologie de Langue Française   01 janvier 2024
GFPC 06-2018: A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
Essai Clinique (Centre François-Baclesse)   31 juillet 2023
DURVALUNG: A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT)
Essai Clinique (AstraZeneca)   27 mars 2023
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Scientific reports   03 mars 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Lung cancer (Amsterdam, Netherlands)   27 février 2023
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Frontiers in oncology   27 février 2023
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]: A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer
Essai Clinique (Roche)   17 février 2023